European Journal of Biomedical and Pharmaceutical Sciences

DENOVO HLA DQ ANTIBODIES IN RENAL TRANSPLANTATION

Varsha Bhagavatprasad Trivedia*, Anis Ahmad Chaudhary, Sarat Kumar Dalaia and Hargovind Laxmishakar Trivedic

ABSTRACT

Donor-specific antibodies (DSA) have proved awell established biomarker predicting antibody against the human leukocyte antigen (HLA)-A, -B, and -DR loci. It has detrimental effect on renal allograft outcomes including high incidence of antibody-mediated rejection, graft dysfunction, inferior graft survival and poor transplant outcomes. Inadequate data is available describing the incidence and impact of denovo HLA-DQ antibodies. 644 renal transplant recipients without pre-transplant donor-specific antibodies over the period of four years from the western part of India were examined. 23% (157/644) patients developed donor-specific antibodies, in which 17.8% (28) had a HLA-class I and 82.6% (129) had class II antibodies.55.8% (72) class II positive patients developed denovo DQ antibodies. The mean of serum creatinine and proteinuria was significantly higher in HLA-DQ antibodies developed patients than those without antibodies.18.05% (13/72) denovo positive patients rejected grafts. The study is conclusive that the donor-specific HLA-DQ antibodies were the most common type detected and these antibodies may contribute to poor graft outcomes.

Keywords: Antibody-mediated Rejection (AMR), Kidney Transplantation, denovo Donor Specific Antibody (dnDSA), HLA-DQ Antibody.